ID2 and GJB2 promote early-stage breast cancer progression by regulating cancer stemness

PurposeDuctal carcinoma in situ (DCIS) is a non-invasive form of breast cancer which could progress to or recur as invasive breast cancer. The underlying molecular mechanism of DCIS progression is yet poorly understood, and appropriate biomarkers to distinguish benign form of DCIS from potentially invasive tumor are urgently needed.MethodsTo identify the key regulators of DCIS progression, we performed gene-expression analysis of syngeneic breast cancer cell lines MCF10A, DCIS.com, and MCF10CA and cross-referenced the targets with patient cohort data.ResultsWe identified ID2 as a critical gene for DCIS initiation and found that ID2 promoted DCIS formation by enhancing cancer stemness of pre-malignant cells. ID2 also plays a pivotal role in survival of the aggressive cancer cells. In addition, we identified INHBA and GJB2 as key regulators for the transition of benign DCIS to aggressive phenotype. These two genes regulate migration, colonization, and stemness of invasive cancer cells. Upregulation of ID2 and GJB2 predicts poor prognosis after breast-conserving surgery. Finally, we found a natural compound Helichrysetin as ID2 inhibitor which suppresses DCIS formation in vitro and in vivo.ConclusionOur results indicate that ID2 is a key driver of DCIS formation and therefore is considered to be a potential target for prevention of DCIS, while INHBA and GJB2 play vital roles in progression of DCIS to IDC and they may serve as potential prognosis markers.

[1]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[2]  A. Iavarone,et al.  Id family of helix-loop-helix proteins in cancer , 2005, Nature Reviews Cancer.

[3]  P. Friedl,et al.  Collective cell migration in morphogenesis, regeneration and cancer , 2009, Nature Reviews Molecular Cell Biology.

[4]  J. Watkinson,et al.  Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1 , 2010, BMC Medical Genomics.

[5]  Fred R. Miller,et al.  Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells , 2004, Breast Cancer Research and Treatment.

[6]  G. Landberg,et al.  High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells , 2005, International journal of cancer.

[7]  J. Cuzick,et al.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial , 2010, The Lancet. Oncology.

[8]  K. Miura,et al.  The Drg-1 gene suppresses tumor metastasis in prostate cancer. , 2003, Cancer research.

[9]  Dhara N. Amin,et al.  Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. , 2010, Cancer research.

[10]  Xin Hu,et al.  ID2 predicts poor prognosis in breast cancer, especially in triple-negative breast cancer, and inhibits E-cadherin expression , 2014, OncoTargets and therapy.

[11]  H. Burger,et al.  Inhibin: definition and nomenclature, including related substances. , 1988, The Journal of clinical endocrinology and metabolism.

[12]  Sean Davis,et al.  Molecular Grading of Ductal Carcinoma In situ of the Breast , 2008, Clinical Cancer Research.

[13]  B. Hogan,et al.  The Id2+ distal tip lung epithelium contains individual multipotent embryonic progenitor cells , 2009, Development.

[14]  M. Thun,et al.  Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. , 2009, The Lancet. Oncology.

[15]  Jun Xia,et al.  Upregulated INHBA expression is associated with poor survival in gastric cancer , 2012, Medical Oncology.

[16]  J. Hopper,et al.  Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. , 1999, The Journal of clinical endocrinology and metabolism.

[17]  E. D. de Vries,et al.  Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. , 2007, Gynecologic oncology.

[18]  Wei Zhang,et al.  Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer , 2017, Oncotarget.

[19]  Enrique Lerma,et al.  ASPN and GJB2 Are Implicated in the Mechanisms of Invasion of Ductal Breast Carcinomas , 2012, Journal of Cancer.

[20]  K. Mimori,et al.  Significance of INHBA expression in human colorectal cancer. , 2013, Oncology reports.

[21]  S. Friedman,et al.  BMP-7 opposes TGF-beta1-mediated collagen induction in mouse pulmonary myofibroblasts through Id2. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[22]  M. Monden,et al.  Expression of Id proteins in human hepatocellular carcinoma: relevance to tumor dedifferentiation. , 2005, International journal of oncology.

[23]  L. Poellinger,et al.  Induction of ID2 Expression by Hypoxia-inducible Factor-1 , 2004, Journal of Biological Chemistry.

[24]  Ofer Reizes,et al.  Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase , 2018, Nature Communications.

[25]  S. Becker-Herman,et al.  Id2 Negatively Regulates B Cell Differentiation in the Spleen1 , 2002, The Journal of Immunology.

[26]  P. Kolatkar,et al.  A Divalent Ion Is Crucial in the Structure and Dominant-Negative Function of ID Proteins, a Class of Helix-Loop-Helix Transcription Regulators , 2012, PloS one.

[27]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[28]  Y. Itahana,et al.  Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. , 2003, Cancer research.

[29]  F. Miller,et al.  MCF10AT: a model for the evolution of cancer from proliferative breast disease. , 1996, The American journal of pathology.

[30]  A. Donfrancesco,et al.  Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma. , 2002, Cancer research.

[31]  T. Klonisch,et al.  Inhibitor of DNA Binding 2 Inhibits Epithelial-Mesenchymal Transition via Up-Regulation of Notch3 in Breast Cancer , 2018, Translational oncology.

[32]  C. Glackin,et al.  TWIST Family of Basic Helix‐Loop‐Helix Transcription Factors Mediate Human Mesenchymal Stem Cell Growth and Commitment , 2009, Stem cells.

[33]  D. Robertson,et al.  Inhibin as a diagnostic marker for ovarian cancer. , 2007, Cancer letters.

[34]  M. Monden,et al.  Aberrant Expression of Connexin 26 Is Associated with Lung Metastasis of Colorectal Cancer , 2008, Clinical Cancer Research.

[35]  H. Friess,et al.  The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. , 1998, Cancer research.

[36]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[37]  F. Miller,et al.  MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. , 2000, Journal of the National Cancer Institute.

[38]  T. Julian,et al.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. , 2011, Journal of the National Cancer Institute.

[39]  J. Massagué,et al.  Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer , 2016, Nature.